Intraperitoneal Paclitaxel as Consolidation Treatment in Ovarian Cancer Patients: A Case Control Study

Publisher： Karger

E-ISSN： 1423-0232|78|1|20-25

ISSN： 0030-2414

Source： Oncology, Vol.78, Iss.1, 2010-02, pp. : 20-25

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sequential Combination of Paclitaxel-Carboplatin and Paclitaxel-Liposomal Doxorubicin as a First-Line Treatment in Patients with Ovarian Cancer

By  

Oncology, Vol. 69, Iss. 4, 2005-12 ,pp. : 348-353

Karger

Access to resources Recommend Favorite

Dose Finding Study for Combination Treatment with Topotecan and Gemcitabine of Patients with Recurrent Ovarian Cancer after Failure of First-Line Chemotherapy with Paclitaxel and Platinum

By  

Oncology Research and Treatment, Vol. 27, Iss. 1, 2004-03 ,pp. : 58-64

Karger

Access to resources Recommend Favorite

Diagnostic value of plasma lysophosphatidic acid levels in ovarian cancer patients: A case–control study and updated meta‐analysis

By  

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (ELECTRONIC), Vol. 41, Iss. 12, 2015-12 ,pp. : 1951-1958

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Phase I Study of Paclitaxel and Epirubicin, without and with Filgrastim, for the Treatment of Platinum-Resistant Advanced Ovarian Cancer

By  

Oncology, Vol. 56, Iss. 4, 1999-05 ,pp. : 267-273

Karger

Access to resources Recommend Favorite

Intraperitoneal chemotherapy of ovarian cancer

By Lowe Thomas   Morgan Robert J  

Women's Health, Vol. 3, Iss. 4, 2007-07 ,pp. : 433-440

Future Medicine

Access to resources Recommend Favorite